VistaGen Therapeutics (VTGN)
(Delayed Data from NSDQ)
$3.29 USD
+0.10 (3.13%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $3.30 +0.01 (0.30%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Cash flow Statements
Fiscal Year End for VistaGen Therapeutics, Inc falls in the month of March.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -29.36 | -59.25 | -47.76 | -17.93 | -20.77 |
Depreciation/Amortization & Depletion | 0.13 | 0.13 | 0.15 | 0.12 | 0.12 |
Net Change from Assets/Liabilities | 1.29 | 2.46 | -1.24 | 3.39 | 0.09 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 2.13 | 6.94 | 3.59 | 2.35 | 4.81 |
Net Cash From Operating Activities | -25.81 | -49.72 | -45.26 | -12.07 | -15.76 |
Property & Equipment | -0.06 | -0.21 | -0.20 | -0.28 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | -0.53 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -0.06 | -0.74 | -0.20 | -0.28 | 0.00 |
Uses of Funds
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 35.93 | -0.01 | 10.49 | 114.48 | 4.01 |
Issuance (Repayment) of Debt | -0.99 | -1.04 | 0.00 | -0.38 | -0.30 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.30 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 93.45 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 128.40 | -1.04 | 10.48 | 114.10 | 4.01 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 102.53 | -51.50 | -34.97 | 101.75 | -11.75 |
Cash at Beginning of Period | 16.64 | 68.14 | 103.11 | 1.36 | 13.10 |
Cash at End of Period | 119.17 | 16.64 | 68.14 | 103.11 | 1.36 |
Diluted Net EPS | -1.52 | -8.51 | -7.51 | -14.71 | -15.02 |
Fiscal Year End for VistaGen Therapeutics, Inc falls in the month of March.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -10.73 | -29.36 | -19.84 | -13.49 | -6.90 |
Depreciation/Amortization & Depletion | 0.02 | 0.13 | 0.09 | 0.06 | 0.03 |
Net Change from Assets/Liabilities | -1.23 | 1.29 | -0.50 | -1.79 | -1.58 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 1.08 | 2.13 | 1.63 | 1.13 | 0.56 |
Net Cash From Operating Activities | -10.87 | -25.81 | -18.62 | -14.08 | -7.89 |
Property & Equipment | -0.04 | -0.06 | -0.03 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -5.43 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -5.47 | -0.06 | -0.03 | 0.00 | 0.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.09 | 35.93 | 129.56 | 36.04 | 1.08 |
Issuance (Repayment) of Debt | 0.00 | -0.99 | -0.99 | -0.99 | -0.20 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 93.45 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 0.09 | 128.40 | 128.57 | 35.05 | 0.88 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -16.25 | 102.53 | 109.92 | 20.97 | -7.02 |
Cash at Beginning of Period | 119.17 | 16.64 | 16.64 | 16.64 | 16.64 |
Cash at End of Period | 102.92 | 119.17 | 126.56 | 37.61 | 9.62 |
Diluted Net EPS | -0.35 | 0.30 | -0.22 | -0.66 | -0.94 |